Cushing’s Disease Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Cushing’s Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Cushing’s Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Cushing’s disease. It projects the future incidence and prevalence rates of Cushing’s disease cases across various populations. The study covers age, gender, and type as major determinants of the Cushing’s disease population. The report highlights patterns in the prevalence of Cushing’s disease over time and projects future trends based on multiple variables.

Cushing’s Disease Understanding: Disease Overview

Cushing’s disease is a rare endocrine disorder caused by an adrenocorticotropic hormone-secreting pituitary adenoma, leading to chronic hypercortisolism. Excess cortisol results in multisystem complications, including central obesity, hypertension, glucose intolerance, osteoporosis, and neuropsychiatric disturbances. The condition is distinct from broader Cushing’s syndrome, which encompasses all causes of cortisol excess. Diagnosis involves biochemical confirmation of hypercortisolism followed by imaging to identify pituitary adenomas. If untreated, Cushing’s disease is associated with significant morbidity and increased mortality, underscoring the importance of early detection and targeted therapeutic intervention.

Cushing’s Disease Epidemiology Perspective

The Cushing’s disease epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Cushing’s disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Cushing’s disease and their trends. The Cushing’s disease detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Norah Kairys, et al., 2023, Cushing’s disease is a rare endocrine disorder with an annual incidence of approximately 2.4 cases per million population.
• The global prevalence of Cushing’s disease remains low, representing a subset of endogenous Cushing’s syndrome cases, with an estimated incidence of 1.2–1.7 cases per million person‑years, according to Tara A. John et al., 2025, based on a Danish 11-year series.
• As per Tara A. John et al., 2025, Cushing’s disease primarily affects adults, with most diagnoses occurring between ages 30 and 49 years, though it can present across all age groups, including rare pediatric cases.
• A strong gender disparity exists, with women affected approximately 3 to 4 times more frequently than men, particularly in pituitary-dependent cases such as Cushing’s disease.

Read more about this report - Request a Free Sample

Country-wise Cushing’s Disease Epidemiology Segment

The Cushing’s disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Cushing’s disease, a rare endocrine disorder, continues to present a measurable yet limited epidemiological burden across developed healthcare systems. According to the World Data, in the United States, incidence ranges from 1.2 to 2.4 cases per million annually, while prevalence reaches approximately 39-40 cases per million. As per Paul Benjamin Loughrey et al., 2024, in the United Kingdom, incidence is estimated at 1.39–1.57 cases per million annually, based on data from Northern Ireland, with females representing approximately 72% of cases.” Overall, these trends underscore consistent detection patterns and a relatively stable patient population landscape.

Cushing’s Disease: Treatment Overview

The primary treatment for Cushing’s disease is transsphenoidal surgical resection of the pituitary adenoma, which offers the highest chance of remission. In cases of incomplete resection or recurrence, adjunctive therapies include radiation therapy and medical management. Pharmacological options target cortisol production or action and include steroidogenesis inhibitors, pituitary-directed agents, and glucocorticoid receptor antagonists. Lifelong monitoring is essential due to recurrence risk and potential hypopituitarism. Emerging therapies focus on improving tumor control and minimizing systemic cortisol exposure, enhancing long-term outcomes and quality of life for affected patients.

Key Questions Answered

• What are the key findings of Cushing’s disease epidemiology in the 8 major markets?
• What will be the total number of patients with Cushing’s disease across the 8 major markets during the forecast period?
• What was the country-wise Cushing’s disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of Cushing’s disease during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of Cushing’s disease during the forecast period of 2026-2035?
• What are the currently available treatments for Cushing’s disease?
• What are the disease risks, signs, symptoms, and unmet needs of Cushing’s disease?

Scope of the Cushing’s disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Cushing’s disease based on several factors.
• Cushing’s Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Cushing’s disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Endogenous Cushing’s Syndrome Epidemiology

Hypertension Drug Pipeline Analysis Report